Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2010

View Archived Issues

Novel Erk/PI3K inhibitors with potent preclinical activity described by AEterna Zentaris

AIN-457 evaluated in clinical studies in patients with noninfectious uveitis

Low efficacy seen with FMP2.1/AS02A malaria vaccine in children

Novel c-Met inhibitors claimed by Vertex

Kalypsys claims novel glucose-dependent insulinotropic receptor (GPR119) ligands

Novel M1 receptor allosteric modulators disclosed by Merck & Co.

Novel AMPK activators disclosed by Merck & Co. and Metabasis

ArQule presents preclinical data on novel Raf kinase B and C inhibitors

LA-480 inhibits HGF-dependent and independent c-Met signaling in preclinical study

Phase II safety/efficacy data on anti-IP-10 antibody in subjects with active UC presented

CR-2017 improves intestinal activity/tolerance in functional gut disorders patients

Italy approves use and reimbursement of afamelanotide for erythropoietic protoporphyria

Concert Pharmaceuticals claims novel deuterated NS3 protease inhibitors

Aastrom treats first patient in phase II tissue repair cell trial in dilated cardiomyopathy

Phase III data point to efficacy of pirfenidone in idiopathic pulmonary fibrosis

FDA sets Zenvia PDUFA date for October 2010

ViroPharma presents final open-label data for Cinryze

ARCA agrees on SPA with FDA for bucindolol study in genotype-defined heart failure

Hemispherx Biopharma plans for phase II Ampligen trials in China

Bristol-Myers Squibb: Q1 product and pipeline update

Encouraging preliminary safety results from phase II trial of pixantrone reported

Emergent to commence phase I trial of anthrax monoclonal antibody

Novel oncolytic virus NTX-010 studied for SCLC in new phase II trial

FDA issues complete response letter for roflumilast

PEARL II study of Esmya meets primary efficacy and safety endpoints

Inhibitex initiates clinical trials of INX-189 in HCV infections

ATX-MS-1467 begins second phase I study in MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...